Get the Stockscreener App
90.49
0.04%
-0.04
After Hours:
90.15
-0.34
-0.38%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Abbott Laboratories stock is traded at $90.49, with a volume of 13.19M.
It is down -0.04% in the last 24 hours and up +3.52% over the past month.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
See More
Previous Close:
$90.53
Open:
$91.19
24h Volume:
13.19M
Relative Volume:
0.97
Market Cap:
$157.62B
Revenue:
$45.13B
Net Income/Loss:
$6.28B
P/E Ratio:
25.21
EPS:
3.5895
Net Cash Flow:
$7.38B
1W Performance:
+2.25%
1M Performance:
+3.52%
6M Performance:
-27.50%
1Y Performance:
-34.47%
1-Day Range:
$90.30
$92.92
1-Week Range:
$87.21
$92.92
52-Week Range:
$81.97
$138.84
Abbott Laboratories Stock (ABT) Company Profile
Name
Abbott Laboratories
Sector
Industry
Phone
(224) 667-6100
Address
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
90.49 | 157.69B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
313.68 | 118.84B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
80.13 | 103.21B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
44.46 | 67.78B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
89.66 | 50.07B | 6.30B | 1.07B | 1.09B | 1.8406 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-22-26 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Oct-10-25 | Initiated | The Benchmark Company | Buy |
| Jul-18-25 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-25 | Initiated | Leerink Partners | Market Perform |
| Oct-08-24 | Initiated | Oppenheimer | Outperform |
| Sep-19-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Downgrade | Edward Jones | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Jul-21-23 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| May-30-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-20-23 | Reiterated | Barclays | Overweight |
| Apr-20-23 | Reiterated | Bernstein | Outperform |
| Apr-20-23 | Reiterated | JP Morgan | Overweight |
| Apr-20-23 | Reiterated | Raymond James | Outperform |
| Apr-20-23 | Reiterated | UBS | Buy |
| Apr-20-23 | Reiterated | Wolfe Research | Underperform |
| Mar-29-23 | Initiated | UBS | Buy |
| Oct-26-22 | Initiated | Mizuho | Neutral |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-06-22 | Initiated | Wolfe Research | Underperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-27-22 | Reiterated | Credit Suisse | Outperform |
| Jan-27-22 | Reiterated | Morgan Stanley | Overweight |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | UBS | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-21 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-14-21 | Initiated | Redburn | Neutral |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Jan-28-21 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-11-20 | Initiated | Wolfe Research | Outperform |
| Jun-01-20 | Downgrade | Goldman | Neutral → Sell |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| Feb-07-19 | Reiterated | BofA/Merrill | Buy |
| Jan-02-19 | Downgrade | Citigroup | Neutral → Sell |
| Nov-30-18 | Upgrade | Goldman | Neutral → Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Jan-30-18 | Reiterated | Citigroup | Neutral |
| Jan-25-18 | Reiterated | Stifel | Buy |
| Jan-25-18 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-19-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-19-17 | Reiterated | Stifel | Buy |
View All
Abbott Laboratories Stock (ABT) Latest News
Got $2,500? 1 Unstoppable Dividend Aristocrat With an Ironclad Moat to Buy - 24/7 Wall St.
Abbott partners with ALZpath on Alzheimer’s blood test - grafa.com
MiniMed Launches Abbott's Instinct Sensors Across European Markets - Yahoo Finance Singapore
ALZpath signs licensing deal with Abbott to develop Alzheimer's blood test - Reuters
Abbott (ABT) Partners with ALZpath for Innovative Alzheimer's Di - GuruFocus
Dividend Stocks That Could Hold Up Better If Rates Stay Higher For Longer - simplywall.st
ALZpath licenses Alzheimer’s antibody to Abbott for diagnostic test - Investing.com
ALZpath licenses Alzheimer’s antibody to Abbott for diagnostic test By Investing.com - Investing.com Canada
How Are Emerging Markets Supporting Abbott's EPD Momentum? - TradingView
Abbott teams with ALZpath on blood test for Alzheimer's disease - Stock Titan
Abbott Laboratories midweek operations focus, NYSE healthcare stock steady on medical devices and di - Ad-hoc-news.de
Whistleblower alleges Abbott bribed Hawaiʻi provider - Medical Buyer
Abbott Laboratories (ABT) Stock Up 3.1% and Still Undervalued -- GF Score: 80/100 - GuruFocus
Missouri appeals court won't send Abbott's appeal of $495 million preterm baby formula verdict to higher court - Reuters
Abbott Laboratories stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Abbott (ABT) Launches New Diabetes Management Systems in Europe - GuruFocus
Abbott Laboratories (NYSE:ABT): Is Market Too Harsh? - Kalkine Media
Abbott Laboratories Employees Credit Union Data Breach Settlement - Claim Depot
Ultrahuman teams up with Abbott Lingo to fix isolated glucose tracking - Wareable
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance Singapore
Abbott Laboratories (ABT) Stock After 33% One-Year Slide Is The Market Overreacting - simplywall.st
3 Monster Stocks to Hold for the Next 10 Years - The Motley Fool
Buy, Sell Or Hold: SBI, Suzlon, Pace Digitek, Zee Entertainment, Urban Company, Abbott Labs — Ask Profit - NDTV Profit
Abbott (ABT) Launches Similac Campaign To Ease Social Media Pressure On Young Parents - Yahoo Finance
Whistleblower: Abbott Laboratories and Hawaiian provider colluded to use more medical devices - HealthExec
ABT Reiterates by Piper Sandler -- Price Target Maintained at $1 - GuruFocus
Similac survey: 80% of young parents feel pressure to be perfect online - Stock Titan
Piper Sandler reiterates Abbott Labs stock rating on growth outlook By Investing.com - Investing.com Canada
Piper Sandler reiterates Abbott Labs stock rating on growth outlook - Investing.com
How to Approach Abbott Stock Following Its Sharp YTD Decline? - The Globe and Mail
Abbott Laboratories earnings calendar builds toward mid-July, shares on NYSE ahead of Q2 update - AD HOC NEWS
Abbott Laboratories (ABT) Stock Could Be 24% Below Fair Value Before Earnings - simplywall.st
Should You Buy Abbott Labs Stock Hand Over Fist Before July 16? - AOL.com
3 US Dividend Growth Stocks With Balance Sheet And Payout Focus - simplywall.st
Whistleblower Alleges Medical Giant Bribed Hawaiʻi Provider - Honolulu Civil Beat
Citi Believes Abbott (ABT) Shares are Undervalued Relative to Business Segments - Insider Monkey
Abbott Laboratories Raised Prices, Prompting Sales Slump - WSJ
Ultrahuman M2 Live: Glucose Tracking Without a Prescription Using Abbott's Lingo Launches in the U.S. - Basic Tutorials
Why Abbott’s Libre Sense glucose sport biosensor keeps endurance athletes wired in - AD HOC NEWS
Abbott Laboratories director John Stratton buys $173,640 in shares - Investing.com
Director at Abbott (NYSE: ABT) buys 2,000 shares in open market - Stock Titan
Abbott Laboratories StockChart focus as shares test support - AD HOC NEWS
Ultrahuman Launches M2 Live in U.S. With Abbott Lingo™ CGM Integration - Digital Health News
Ultrahuman launches M2 Live with Abbott's Lingo glucose sensor - t2ONLINE
NEC Baby Formula Lawsuit April 2026 | $70M Abbott Verdict - Consumer Notice
Abbott Laboratories stock underperforms Wednesday when compared to competitors - MarketWatch
ABT Stock Quote Price and Forecast - CNN
Abbott Laboratories stock outperforms competitors on strong trading day - MarketWatch
Abbott's CGM Growth Story Stays Intact Despite Q1 Moderation - Yahoo Finance
Five-Year Tally: Abbott Laboratories Stock Delivers $28 Bil Gain - Trefis
Abbott Laboratories Stock Capital Return Hits $28 Bil - Trefis
Abbott Laboratories Stock (ABT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.19%
0.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):